<DOC>
	<DOCNO>NCT03105804</DOCNO>
	<brief_summary>To determine rate amount nicotine uptake 10-minute ad libitum use four different market electronic cigarette . Furthermore , measure overall product liking subject assess potential willingness seek Electronic Cigarette ( EC ) future .</brief_summary>
	<brief_title>CSD170301 : An Unblinded , Parallel , Randomized Study Assess Nicotine Uptake Smokers From Four Different Electronic Cigarettes</brief_title>
	<detailed_description>This single-center , randomize , open-label , parallel study 140 healthy adult subject , consist 35 subject per market EC product , enrol . Subjects evaluate plasma nicotine uptake , well overall product liking . The study involve use four ( 4 ) market EC product tobacco consumer exclusive smoker ( i.e. , naïve EC user ) dual user cigarette ECs ( i.e. , intermittent EC user ) .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>1 . Able read , understand , willing sign Informed Consent Form ( ICF ) complete questionnaire write English . 2 . Generally healthy male female , 21 60 year age , inclusive , Screening Visit . 3 . Subjects must meet one ( b ) follow tobacco use condition : 1 . Exclusive cigarette smoker selfreports smoke least ( ≥ ) 10 cigarette per day least 6 month prior Screening Visit . Brief period abstinence 30 day prior Screening due illness , quit attempt clinical study participation allow discretion Investigator . 2 . Dual user combustible cigarette ECs selfreports : 1 . Smoking least ( ≥ ) 10 cigarette per day least 6 month prior Screening Visit . Brief period abstinence 30 day prior Screening due illness , quit attempt clinical study participation allow discretion Investigator 2 . Using nicotinecontaining cigalike EC tank system EC either daily least weekly least 3 month prior Screening Visit . 4 . Willing confine overnight abstain tobacco nicotine contain product use 12 hour prior IP use Study Discharge . 5 . Willing use assign IP study accord protocol . 6 . Expired breath carbon monoxide ( ECO ) level ≥10 part per million ( ppm ) Screening Visit Study Day 1 . 7 . Positive urine cotinine test Screening Visit Study Day 1 . 8 . No intent quit smoke vaping Screening Study Day 2 . 9 . Females childbearing age must willing use form contraception acceptable Investigator time sign informed consent Study Discharge , surgically sterile least 90 day prior Screening Visit . 1 . Presence clinically significant unstable/uncontrolled acute chronic medical condition Screening Visit , determine Investigator , would preclude subject participate safely study ( e.g. , uncontrolled hypertension , diabetes , asthma lung disease , cardiac disease , neurological disease psychiatric disorder ) base safety assessment clinical laboratory test , pregnancy test , medical history , physical/oral examination . 2 . At risk heart disease , determine Investigator . 3 . Systolic blood pressure ≥150 mmHg diastolic blood pressure ≥ 95 mmHg , measure seat 5 minute . 4 . Weight ≤ 110 pound . 5 . Poor peripheral venous access . 6 . Use medicine treatment depression asthma ( e.g. , paroxetine [ Paxil® ] , montelukast [ Singulair® ] , albuterol [ Proventil® HFA ] ) , deem clinically significant Investigator . 7 . Use medication substance aid smoke cessation , include limited nicotine replacement therapy ( NRT ) ( e.g. , nicotine gum , lozenge , patch ) , varenicline ( Chantix® ) , bupropion ( Wellbutrin® , Zyban® ) , lobelia extract within 30 day prior Screening Visit . 8 . History presence hemophilia bleed disorder . 9 . History presence clot disorder concomitant use anticoagulant ( e.g. , clopidogrel [ Plavix® ] , warfarin [ Coumadin® , Jantoven® ] aspirin [ &gt; 325 mg/day ] ) . 10 . Participation another clinical trial within ( ≤ ) 30 day prior time consent . The 30day window subject derive date last study event previous study time consent current study . 11 . Positive test human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HBsAg ) , Hepatitis C virus antibody ( antiHCV ) . 12 . Females positive pregnancy test , pregnant , breastfeeding , intend become pregnant course study . 13 . Females ≥ 35 year age currently use systemic , estrogencontaining contraception hormone replacement therapy . 14 . A positive urine drug screen without disclosure correspond concomitant medication ( ) Screening Visit Study Day 1 . 15 . A positive alcohol breathalyzer result Screening Visit Study Day 1 . 16 . Employed tobacco nicotine company , study site , handle tobacco nicotinecontaining product part job . 17 . Determined Investigator inappropriate study , include subject unable communicate unwilling cooperate clinical staff .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>